

# UCSF

## UC San Francisco Previously Published Works

### Title

The Y-linked proto-oncogene TSPY contributes to poor prognosis of the male hepatocellular carcinoma patients by promoting the pro-oncogenic and suppressing the anti-oncogenic gene expression.

### Permalink

<https://escholarship.org/uc/item/8j837946>

### Authors

Kido, Tatsuo

Lau, Yun-Fai

### Publication Date

2019

### DOI

10.1186/s13578-019-0287-x

Peer reviewed

RESEARCH

Open Access



# The Y-linked proto-oncogene TSPY contributes to poor prognosis of the male hepatocellular carcinoma patients by promoting the pro-oncogenic and suppressing the anti-oncogenic gene expression

Tatsuo Kido<sup>1,2</sup> and Yun-Fai Chris Lau<sup>1,2\*</sup> 

## Abstract

**Background:** Liver cancer is one of the major causes of cancer death worldwide, with significantly higher incidence and mortality among the male patients. Although sex hormones and their receptors could contribute to such sex differences, the story is incomplete. Genes on the male-specific region of the Y chromosome could play a role(s) in this cancer. TSPY is the putative gene for the gonadoblastoma locus on the Y chromosome (GBY) that is ectopically expressed in a subset of male hepatocellular carcinomas (HCCs). Although various studies showed that TSPY expression is associated with poor prognosis in the patients and its overexpression promotes cell proliferation of various cancer cell lines, it remains unclear how TSPY contributes to the clinical outcomes of the HCC patients. Identifying the downstream genes and pathways of TSPY actions would provide novel insights on its contribution(s) to male predominance in this deadly cancer.

**Results:** To determine the effects of TSPY on HCC, a TSPY transgene was introduced to the HCC cell line, HuH-7, and studied with RNA-Seq transcriptome analysis. The results showed that TSPY upregulates various genes associated with cell-cycle and cell-viability, and suppresses cell-death related genes. To correlate the experimental observations with those of clinical specimens, transcriptomes of male HCCs with high TSPY expression were analyzed with reference to those with silent TSPY expression from the Cancer Genome Atlas (TCGA). The comparative analysis identified 49 genes, which showed parallel expression patterns between HuH-7 cells overexpressing TSPY and clinical specimens with high TSPY expression. Among these 49 genes, 16 likely downstream genes could be associated with survival rates in HCC patients. The major upregulated targets were cell-cycle related genes and growth factor receptor genes, including CDC25B and HMMR, whose expression levels are negatively correlated with the patient survival rates. In contrast, PPARGC1A, SLC25A25 and SOCS2 were downregulated with TSPY expression, and possess favorable prognoses for HCC patients.

**Conclusion:** We demonstrate that TSPY could exacerbate the oncogenesis of HCC by differentially upregulate the expression of pro-oncogenic genes and downregulate those of anti-oncogenic genes in male HCC patients, thereby contributing to the male predominance in this deadly cancer.

\*Correspondence: Chris.Lau@UCSF.edu

<sup>1</sup> Division of Cell and Developmental Genetics, Department of Medicine, Veterans Affairs Medical Center, University of California, San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA

Full list of author information is available at the end of the article



**Keywords:** Hepatocellular carcinoma, TSPY, Y-chromosome, Male predominance, Transcriptome analysis, TCGA dataset, Datamining

## Background

The testis specific protein Y-encoded (TSPY) is a tandemly repeated gene (>30 times) located within the gonadoblastoma locus on the Y chromosome (*GBY*), which predisposes XY patients with disorders of sexual development (DSDs) to gonadoblastoma development [1–3]. TSPY encodes a protein harboring a SET/NAP domain, initially identified in the SET oncoprotein and nucleosome assembly proteins (NAPs) [4, 5]. SET/NAP proteins play important roles in transcriptional regulation, chromatin assembly, histone chaperone, and cell-cycle regulation [6–10]. Previously, we demonstrated that TSPY interacts with the cyclin-B/CDK1 complex, eukaryotic translation elongation factor 1A (EEF1A), and androgen receptor (AR) via its SET/NAP domain, and enhances the respective functions of these binding partners [11–13]. Overexpression of TSPY accelerates cell proliferation in various cancer cell lines [11, 13, 14]. Further, TSPY directly binds to the chromatin at its own exon-1 region and amplifies its own expression in a positive-feedback manner [15], suggesting the potential role of TSPY as a transcriptional regulator. Others showed that TSPY could suppress TP53 functions and enhance cell proliferation by inhibiting USP7, a protective deubiquitinase for TP53 [16]. TSPY is predominantly expressed at the early-stages of male germ cells, i.e. gonocytes and prespermatogonia at fetal testis [17] and spermatogonia and spermatocytes in adult testis [18]. It is postulated to participate in mitotic proliferation and meiotic division of male germ cells [19]. Importantly, TSPY is frequently expressed in germ cell tumors including gonadoblastoma, seminoma, and the carcinoma-in situ/intratubular germ cell neoplasia unclassified (CIS/ITHCNU), the precursor for all germ cell tumors [20–24]. Since TSPY is the primary gene located within *GBY* locus and is expressed in gonadoblastoma, TSPY is the putative gene for this oncogenic locus and could predispose dysfunctional germ cells to tumor development in dysgenetic gonads. Indeed, transgenic mouse studies showed that ectopic expression of TSPY in ovaries resulted in gonadoblastoma-like structures in female mice [25]. Significantly, TSPY is also expressed in various types of somatic cancer; including prostate cancer, lung cancer, and hepatocellular carcinoma (HCC) [26–30]. Accordingly, TSPY could also promote oncogenic initiation and/or progression of somatic cancers in male patients.

Liver cancer causes more than 700,000 cancer deaths each year worldwide [31, 32]. Significantly the incidence

and mortality of HCC is much higher in males than females, with greater than threefold difference [32–34]. Both sex hormones and/or their receptors and the sex chromosome genes have been postulated to contribute to such sex differences, the mechanisms of which, however, could be quite complex [35–40]. As a proto-oncogene on the Y chromosome, TSPY is expressed in a subclass of male HCC cases (30–40%), frequently associated with the global hypomethylation of the genomic DNA, including its own promoter sequence [27, 28]. However, beside its general functions in cell proliferation and growth, the exact mechanism(s) by which TSPY exerts on the oncogenic processes in HCC patients remains unknown.

In order to determine the effects of TSPY expression on HCC, we overexpressed TSPY in the HCC cell line, HuH-7, and analyzed the differential gene expression patterns between HuH-7 cells expressing and non-expressing the TSPY transgene using transcriptome analysis, and correlated the results with those derived from comparative study between the male HCC cases with high TSPY expression and non-expression (silent) from the Cancer Genome Atlas (TCGA) [27, 41]. We identified 16 genes that were potentially regulated by TSPY and their differential expression could be correlated with the prognoses of the HCC patients. Among these genes, TSPY upregulates cell-cycle regulators and components of cell-division machinery, e.g. BUB1, CDC25B, CDC45, CENPA, PRC1, PRIM1, RRM2, and SPC24, as well as growth factor receptors, e.g. ADGRD1 and HMMR, which are associated with unfavorable prognosis and poor survivals of the patients while the expression of PPARGC1A, SLC25A25 and SOCS2 are inversely correlated with TSPY expression but are associated with favorable prognosis and better survival of the patients. Our results suggest that ectopic expression of the Y-located TSPY could promote the expression of pro-oncogenic genes and suppression of anti-oncogenic genes in HCC, thereby contributing to the male predominance of this deadly cancer.

## Methods

### Cell culture and lentiviruses

HuH-7 cells, a human hepatocellular carcinoma cell line, were cultured in DMEM medium containing 10% tet system-approved fetal bovine serum (FBS; Clontech) and antibiotics cocktail (100 U/mL penicillin and 100 µg/mL Streptomycin). Lentiviruses for the expression of TSPY and EGFP with tet-ON system were prepared as described previously [13, 42]. Cells were transduced with

lentiviral particles containing the expression vectors, FUW-tetO-TSPY-ires-EGFP or FUW-tetO-EGFP with pFUW-M2rtTA. The ires sequences in the FUW-tetO-TSPY-ires-EGFP vector enable ribosome complex-binding and simultaneous expression of both TSPY and EGFP genes in a bicistronic cassette. The transduced cells were cultured in the absence of doxycycline (Dox) until analyses. The transduced cells were cultured in the presence of 1  $\mu\text{g}/\text{mL}$  Dox (Sigma-Aldrich) to induce the expression of both TSPY and EGFP (Fig. 1a). For cell proliferation analyses, cells were seeded at 2000 cells/well in 96-well plates and cultured in the presence of 0.5  $\mu\text{g}/\text{mL}$  Dox. The cell viability was monitored at the indicated time points using the CellTiter 96 Aqueous One Cell Proliferation Assay kit (Promega), according to the instructions from the manufacturer.

### Western blot

Western-blot was performed as described previously [43], using anti-TSPY mouse monoclonal antibody (clone 17, generated in our laboratory) and anti- $\beta$ -actin mouse monoclonal antibody (clone AC-15, Sigma-Aldrich). Immunoreactive signals were visualized by IRDye680RD conjugated anti-mouse IgG antibody, and recorded by the Odyssey system (LI-COR, Lincoln, NE).

### Immunofluorescence


Immunofluorescence was performed as described previously [11]. Briefly, cells were fixed with 4% paraformaldehyde-PBS solution for 5 min, and permeabilized by methanol treatment. After blocking with 3% bovine serum albumin (Sigma)-PBS solution for 1 h, the slides were incubated with primary antibodies at

4  $^{\circ}\text{C}$  overnight. The primary antibodies used for immunofluorescence were anti-GFP goat IgG (Abcam) and anti-TSPY mouse monoclonal antibody (clone 17). The immunoreactive signals were visualized by Alexa Fluor 488 conjugated anti-goat IgG antibody (Invitrogen) and Alexa Fluor 594 conjugated anti-mouse IgG antibody respectively. Nuclear DNA was stained with 4',6-diamidino-2-phenylindole (DAPI) (Roche Applied Science). Fluorescent images were recorded with a Nikon Eclipse Ti fluorescence microscope and image acquisition workstation (Nikon instrument Inc., Melville, NY).

### RNA preparation and RNA-Seq transcriptome analysis of the transduced HuH-7 cells

Total RNA was isolated from the cells cultured in a 6-well plate (9.6  $\text{cm}^2$  surface area) at 24 h after Dox-induction using TRIZOL-Plus RNA purification kit (ThermoFisher Scientific, NY). One  $\mu\text{g}$  total RNA from each triplicate sample was used for the library preparation using KAPA Stranded mRNA-Seq kit (Kapa Biosystems, MA). Libraries were indexed (bar-coded) with NEBNext multiplex primers for Illumina (New England Biolabs, CA). The libraries were subjected to 75 single-end read cycles of sequencing on the NextSeq 500 (Illumina, CA). All procedures were performed according to the manufacturer's instructions.

The sequence reads were mapped onto the Ensembl GRCh37 (hg19) human reference genome using TopHat (version 1.0.1) [44], after quality assessment by FastQC program (version 0.11.4) [45]. The mapped reads were summarized and calculated to the count reads, which were then quantitated as the expression levels using the featureCounts (version 1.5.1) program [46].



Normalization and differential gene expression analysis were performed using an R package TCC [47].

Gene expression enrichment analysis, functional network analyses and pathway analyses were performed with Ingenuity Pathways Analysis (IPA) (Ingenuity Systems, build version 463341M) and DAVID bioinformatics resources [48]. A schematic diagram of cell cycle pathway was downloaded from KEGG website (<https://www.genome.jp/kegg/>) with permission [49].

#### Data set and data mining analysis of HCC specimens from TCGA

The RNA-Seq gene expression data and associated clinical information of HCC cases at the Cancer Genome Atlas (TCGA) data portal were downloaded from the UCSC Xena Browser [50]. The datasets included 50 non-tumor samples (28 male cases and 22 female cases) and 371 tumor samples (250 male cases and 121 female cases). The expression levels were calculated as RSEM normalized read count [51]. The survival information of the respective HCC patients was obtained from the Human Protein Atlas (HPA) data portal [52], except for classification of the high TSPY-expressing patients and the TSPY-silent patients. Statistical analyses were performed with the Prism6 program (GraphPad Software, Inc., La Jolla, CA).

## Results

### TSPY-overexpression enhances cell proliferation in HuH-7 cells

The effects of TSPY in HCC were examined in the HCC HuH-7 cells, which were transduced with Tet-On lentiviral vectors overexpressing TSPY-ires-EGFP and EGFP alone under doxycycline-induced conditions, hereby designated as HuH-7-tetON-TSPY and HuH-7-tetON-EGFP respectively (Fig. 1a). HuH-7-tetON-EGFP cells served as a control for all experiments in the study. Western-blot analyses confirmed the expression of TSPY and EGFP being appropriately induced by Dox in the culture media (Fig. 1b). Immunocytochemical analyses showed that the TSPY protein was localized in both cytoplasm and nuclei (Fig. 1c), consistently with the observations in clinical HCC samples [28]. Cell proliferation assays showed that overexpression of TSPY promoted cell proliferation in HuH-7 cells (Fig. 1d), as previously reported on other cancer cell types [13, 14, 16].


### TSPY upregulated various cell-cycle related genes and suppressed tumor suppressor genes in HuH-7 cells

To explore the mechanisms by which TSPY regulates the molecular events in HuH-7 cells, we had performed

a transcriptome analysis using the Illumina RNA-Seq platform. The mRNAs were isolated from respective HuH-7 cells ( $n=3$ ) overexpressing TSPY and EGFP alone at 24 h after Dox administration, and analyzed in biological triplicates with RNA-Seq strategy [13]. The differentially expressed genes (DEGs) between HuH-7-tetON-TSPY and HuH-7-tetON-EGFP cells were identified with false discovery rate (FDR)  $<0.05$  by the TCC analysis, Student's  $t$ -test  $P$ -value  $<0.05$ , expression level of  $\log_2[\text{expression read count}] > 3.32$ , and  $\text{Log}_2[\text{fold change}] > 0.6$ , resulting in a total of 1884 DEGs consisting of 1139 up-regulated genes and 745 down-regulated genes (Fig. 2a and Additional file 1: Table S1). The DEGs were subsequently mapped onto the KEGG pathway, representing molecular interaction and relation network, using the DAVID gene-annotation enrichment analysis software [48, 49]. The results showed that the pathways of metabolic pathways, steroid biosynthesis, glycosaminoglycan degradation, cell cycle, and bile secretion, were enriched at Benjamini-Hochberg  $\text{FDR} < 0.05$ , suggesting that these pathways could be affected by TSPY overexpression in HuH-7 cells (Fig. 2b).

Using a set of DEGs derived from a more stringent expression level, we further analyzed the TSPY effects with the Ingenuity Pathways Analysis (IPA) program [53, 54]. Our results showed that the biological functions remarkably affected by TSPY overexpression were pathways associated with cell-cycle and cell viability (Additional file 2: Figure S1a and S1b). Noticeably, the pathways of necrosis and cell-death were inhibited (Additional file 2: Figure S1b, blue columns) while the pathways associated with cellular interphase processes and cell-survival were enhanced (Additional file 2: Figure S1b, red columns), as indicated by the  $|z\text{-scores of } - \text{ and } +| > 2$  for significance in inhibition and activation respectively. The IPA hepatotoxicity analysis demonstrated that the TSPY-induced DEGs were significantly associated with liver cancer development (Additional file 2: Figure S1c). Altogether, both gene annotation/ontology programs consistently suggested that the pathways of cell-cycle and cell viability could be mostly affected by TSPY overexpression in HuH-7 cells. To further illustrate the various cell cycle genes being affected by TSPY, we mapped the associated DEGs onto the KEGG cell-cycle pathway [48, 49]. Our results showed that the tumor suppressors CDKN1A (also known as Cip1 and p21) and GADD45 were down-regulated while various positive cell-cycle regulators and components for DNA replication, including cyclin-B, cyclin-D, CDK1, CDC25B, and MCMs, were upregulated by TSPY-overexpression (Fig. 2c).





**Fig. 2** Transcriptome and DAVID analyses of the HuH-7-tetOn-TSPY cells. **a** MA-plots showing the differentially expressed genes (DEGs) between HuH-7-tetOn-TSPY cells and HuH-7-tetOn-EGFP cells. Genes plotted within the areas of  $\text{Log}_2[\text{expression level}] > 3.32$  and  $|\text{Log}_2[\text{fold change}]| > 0.6$  (red) were analyzed as differentially expressed genes (DEGs). **b** DAVID gene-annotation enrichment analysis identified top 5 KEGG pathways enriched in DEGs with  $\text{FDR} < 0.05$ ;  $\text{FDR}$  = false discovery rate or corrected P-value. **c** Mapping of the 26 DEGs on the KEGG cell-cycle pathway [49]. Red indicates the upregulated genes and green indicates the downregulated genes in the Dox-treated HuH-7-tetON-TSPY cells

Overall, the transcriptome analysis of the HuH-7 cells overexpressing TSPY showed that TSPY could promote cell proliferation and viability by directly or indirectly


augmenting a pro-oncogenic gene expression pattern consistent with the results of cell-proliferation assay (Fig. 1d).

### High expression of TSPY is associated with poor survival rate in male HCC patients

To correlate the effects of TSPY on the gene expression patterns and clinical outcomes in the HCC patients, we had examined the transcriptomes and the corresponding clinical data of the HCC samples from the Cancer Genome Atlas (TCGA) [27, 41]. Among the 250 male HCC cases, the top 34 cases expressed TSPY at the highest level (expression read count >50) and were classified as the male TSPY-high group, and 180 cases without TSPY expression were classified as the male TSPY-silent group (Fig. 3a). The survival data showed that the survival rate of the male TSPY-high group was significantly lower than that of male TSPY-silent group (Log-rank test P-value = 0.0005) (Fig. 3b), suggesting that TSPY could be directly or indirectly involved in the progression of HCC and survival of the patients. Further and importantly, the survival rate of the male TSPY-high group was significantly lower than that of female group (Log-rank test P-value = 0.0164), while there was not significant difference between male TSPY-silent group and female group (Log-rank test P-value = 0.0671) (Fig. 3b).

### Correlation of the differentially expressed genes between the TSPY overexpression in HuH-7 cells and TSPY-high group male HCC patients

To identify the common DEGs associated with both TSPY overexpression in HuH-7 cells and TSPY high expression in HCC patients, we had analyzed the differential gene expression patterns of HuH-7 cells overexpressing TSPY versus EGFP and those of TSPY-high group versus TSPY-silent group in clinical HCC tissue samples. The datamining of the TCGA datasets identified 692 DEGs with a cut-off differential expression level at  $|\log_2[\text{difference}]| > 0.6$  and a P value < 0.05 between the male TSPY-high group and the male TSPY-silent group of HCC (Fig. 3c and Additional file 3: Table S2). By comparing these DEGs in HCCs to those derived from HuH-7 overexpressing TSPY (Fig. 2a), 49 DEGs were identified to share similar expression patterns, i.e. either up or down, between HuH-7 overexpressing TSPY and TSPY-high group in clinical HCC specimens (Fig. 3d and Additional file 4: Table S3). To further identify those potentially play important roles in HCC, these 49 genes were further analyzed with respect to the correlation



**Fig. 3** Identification of the TSPY downstream genes associated with clinical outcomes in primary HCC. **a** Based on the TSPY expression level, male HCC cases were classified into the TSPY-high group (n = 36, expression count > 50) and the TSPY-silent group (n = 180, expression count = 0). **b** Survival curves showing that the survival rates of the male TSPY-high group (red), male TSPY-silent group (blue), and female group (gray). Log-rank test P-values are indicated. **c** Volcano plot representing the DEGs between TSPY-high and TSPY-silent HCC groups (red plots). **d** The diagram shows the workflow to identify the downstream genes regulated by TSPY in HCC tissues. The genes whose expression levels consistently correlated with the TSPY expression level in both HuH-7 cells and clinical TSPY-high HCC tissue samples were selected as described in the body text. Sixteen genes (red), whose expression patterns correlated with that of TSPY, were identified to be associated with clinical outcomes.

of their expression patterns with the mortality of HCC patients (Fig. 3d) [52]. Such additional analysis identified 16 DEGs whose expression levels were associated with the survival rates of HCC patients (Fig. 3d and Table 1). Three genes, PPARGC1A, SLC25A25 (also known as MCSC), and SOCS2, associated with favorable prognoses and good patient survivals were downregulated by TSPY. PPARGC1A and SOCS2 are considered to be tumor suppressors in liver cancer [55–59], while SLC25A members are involved in mitochondrial  $Ca^{2+}$  signaling important for hepatocyte physiology [60, 61]. The expression patterns of the remainder 13 genes were unfavorable for patient survival and were upregulated by TSPY (Table 1, and Figs. 3, 4, Additional file 5: Figure S2, and Additional file 6: Figure S3). These pro-oncogenic genes included various cell-cycle related genes, e.g. BUB1, CDC25B, CDC45, CENPA, PRC1, PRIM1, RRM2, and SPC24, that participate in DNA replication and G<sub>2</sub>/M-phases progression respectively (Table 1 and Additional file 7: Table S4), which are consistent with our previous observations that

TSPY accelerates G<sub>2</sub>/M-transition [14] and enhances the mitotic cyclin B-CDK1 phosphorylation activities [12, 62]. In addition, growth factor receptors, e.g. ADGRD1 (also known as GPR133) and HMMR (also known as RHAMM), and components of DNA repair machinery, e.g. EXO1 and RAD51, were also upregulated by TSPY and negatively associated with patient survival (Table 1 and Figs. 3, 4, Additional file 5: Figure S2, and Additional file 6: Figure S3). These results suggest that the ectopically expressed TSPY could exacerbate oncogenesis and progression in HCC by stimulating downstream unfavorable (pro-oncogenic) but repressing favorable (anti-oncogenic) gene expression in the tumors.

#### TSPY promotes pro-oncogenic gene expression and poor survival of male HCC patients

Comparison of the gene expression levels among respective TSPY-related groups showed that the expression levels of the unfavorable/pro-oncogenic genes, e.g. ADGRD1, CDC25B, CDC45, EXO1, HMMR, PRIM1,


**Table 1 Sixteen downstream genes potentially regulated by TSPY and associated with prognosis in HCC patients**

Category	Gene symbol (alias)	Function	Effect by TSPY	Effect to HCC survival
DNA replication	CDC45	An initiator for chromosomal DNA replication by recruiting DNA polymerase to chromatin	Upregulated	Unfavorable
	PRIM1	A component of the DNA polymerase synthesizing RNA primers for the Okazaki fragments	Upregulated	Unfavorable
	RRM2	A ribonucleotide reductase catalyzing the biosynthesis of deoxyribonucleotides from ribonucleotide	Upregulated	Unfavorable
G <sub>2</sub> /M progression	BUB1	A Ser/Thr protein kinase playing a central role in the spindle checkpoint.	Upregulated	Unfavorable
	CDC25B	A Thr protein phosphatase activating CDC2 and CDK1, playing key roles in initiation of G <sub>2</sub> /M phase	Upregulated	Unfavorable
	CENPA	A centromere protein required for the recruitment of kinetochore proteins to centromere	Upregulated	Unfavorable
	PRC1	A key regulator of cytokinesis by forming spatiotemporal midzone with KIF14, central spindle and midbody	Upregulated	Unfavorable
	SPC24	A component of NDC80 complex organizing the stable microtubule binding sites of the kinetochore	Upregulated	Unfavorable
Membrane receptors	ADGRD1 (GPR133)	A G-protein-coupled membrane receptor	Upregulated	Unfavorable
	HMMR (RHAMM)	A receptor of hyaluronic acid (HA); intracellular HMMR plays a role in cytokinesis	Upregulated	Unfavorable
DNA repair and recombination	EXO1	A DNA exonuclease functioning in DNA mismatch repair	Upregulated	Unfavorable
	RAD51	A component of the DNA repairing machinery in homologous recombination	Upregulated	Unfavorable
Others	EGLN3 (PDH3)	A prolyl hydroxylase regulating the activities of HIFs	Upregulated	Unfavorable <sup>a</sup>
	PPARGC1A (PGC-1a)	A transcriptional coactivator of PPARgamma	Downregulated	Favorable
	SLC25A25	A calcium-dependent mitochondrial solute carrier	Downregulated	Favorable
	SOCS2 (MCSC)	A negative regulator of cytokine receptor signaling	Downregulated	Favorable

Full table is presented as Additional file 7: Table S4

<sup>a</sup> The role of EGLN3 in HCC seems to be controversial





RAD51, RRM2, and SPC24, were significantly higher in the male TSPY-high group HCCs than female HCCs, while the expression level of the favorable/anti-oncogenic gene, e.g. PPARGC1A, was significantly lower in the male TSPY-high group HCCs than the female HCCs (Fig. 4 and Additional file 6: Figure S3). However, there was no significant difference in the expression levels of the 16 downstream genes between the male TSPY-silent group HCCs and female HCCs, except EGLN3 and SPC24 (Fig. 4 and Additional file 6: Figure S3). These results suggest that TSPY could differentially affect the expression levels of pro-oncogenic and unfavorable genes in male HCCs, as compared to those in female HCCs. Indeed, as described above, the survival data indicate that, while there was no significant difference between female HCC group and the male TSPY-silent HCC group, the survival ratio of the male TSPY-high HCC group was significantly lower than that of female HCC group (Log-rank test P-value = 0.0164) with 3 years survival ratio of 35% in the male TSPY-high HCC group and 60–70% in female HCC and the male TSPY-silent HCC groups respectively

(Fig. 3b). These observations support the hypothesis that TSPY could be a male-specific genetic risk factor and its aberrant and epigenetic activation contributes to the oncogenic processes and the male predominance of HCC.

## Discussion

Recent studies have provided significant evidence demonstrating the sex differences in various diseases, including cardiovascular, inflammatory and neurodegenerative diseases, as well as numerous types of cancer [38, 63–69]. Currently, the mechanisms contributing to such sex differences are still largely unknown. Liver cancer is one of the most male predominant cancers with men having approximately three to sixfolds higher incidence and mortality than women, depending on the geographic locations [32–34]. The sex hormones and their receptors have been postulated to play key roles in such sex difference in HCC [39, 40, 70, 71]. Female hormones, i.e. estrogen and prolactin, have been proposed to suppress HCC development by reducing the activities of

inflammatory pathways, such as IL-6 and TNF signaling cascades in liver [36, 37, 72]. In contrast, male hormones, i.e. androgens, could stimulate hepatitis B virus replication and expression of the HBV viral oncoprotein HBx via androgen receptor actions, resulting in exacerbation of HCC development [73–77]. Since it is estimated that 50–80% of HCC patients could be associated with HBV-infection, the androgen-dependent upregulation of the viral oncoprotein HBx might contribute to the male predominance of HCC. Notably, sex differences in HCC still observed between men and women after menopause age, and various clinical trials targeting androgen receptor showed limited effects on HCC progression [33, 78]. Hence, in addition to sex hormones and their receptors, genetic factors could also be important for the male predominance of HCC. Such genetic factors include single nucleotide polymorphisms (SNPs) on autosomal genes correlating with the sex difference of HCC [79, 80]. Further, we demonstrated that an X-encoded tumor suppressor TSPX, the homologue of TSPY on the X chromosome, could bind to and promote the proteasomal degradation of the viral oncoprotein HBx [81]. Since men have only one X-chromosome, inactivation and/or mutation of such tumor suppressor gene could increase the risk of HBx-mediated HCC in men [38, 81].


TSPY is a male specific proto-oncogene on the Y chromosome and is ectopically expressed in a subclass of male HCC cases (30–40% of cases) [27, 28, 30]. Although such TSPY expression could be related to its pro-oncogenic functions, such as acceleration of cell proliferation, stimulation of protein synthesis and cell growth, suppression of TP53 functions, and exacerbation on androgen receptor transactivation [11–14, 16], its downstream molecular effects have not been fully explored. We previously identified the TSPY co-expression network genes that are frequently upregulated together with TSPY in multiple somatic cancers, including HCC, and are associated with global DNA hypomethylation [27]. Using transcriptome analyses on the HuH-7 HCC cells overexpressing TSPY and those of clinical HCC specimens from the TCGA database, we identified 16 genes that were likely regulated directly or indirectly by TSPY in HCC cells and contributed to poor prognosis of HCC patients (Table 1, and Fig. 4 and Additional file 5: Figure S2). These TSPY-regulated genes include numerous cell-cycle related genes and growth factor receptors (Table 1 and Fig. 5). Importantly, the expression levels of the unfavorable genes, e.g. ADGRD1, CDC25B, CDC45, EXO1, HMMR, PRIM1, RAD51, RRM2, and SPC24, were significantly

higher in the male TSPY-high group HCCs than TSPY-silent/female group HCCs, while the expression level of the favorable gene, e.g. PPARGC1A, was significantly lower in the male TSPY-high group HCCs than female HCCs (Fig. 4 and Additional file 6: Figure S3). Previous studies demonstrated the oncogenic properties of ADGRD1, CDC25B, HMMR, PRIM1, RAD51, RRM2, and SPC24, in HCC and/or other somatic cancers [82–91] (Additional file 7: Table S4). Indeed, the small molecule inhibitors against CDC25 and RRM2 significantly inhibited cell proliferation in HuH-7 cells, and the TSPY-overexpression relieved the effects of these inhibitors (Additional file 8: Figure S4). Our results strongly suggest that TSPY is a male-specific genetic factor that exacerbates HCC oncogenesis by stimulating the expression of these downstream pro-oncogenic genes, thereby contributing to the male predominance of HCC. Such postulation is supported by the fact that the survival rate of the male TSPY-high HCC group was significantly lower than those of male TSPY-silent and female HCC groups (Fig. 3b).

HMMR was originally identified as the receptor for hyaluronan (HA), a component of extracellular matrix, and it is frequently upregulated in various cancer types, including colon cancer, bladder cancer, prostate cancer, and liver cancer [83, 92–95]. The high HMMR expression correlates with cancer growth, metastasis, and poor prognosis in these types of cancer [83, 92–95]. The level of extracellular HA is elevated according to the progression of liver fibrosis, which is a pathological precondition for HCC [96]. The intracellular HMMR participates in mitotic spindle pole formation and cytokinesis [97]. The identification of HMMR as a downstream gene upregulated by TSPY suggests that it could be involved in the initiation and progression of HCC via its stimulation of the HA-HMMR signaling cascade, in addition to oncogenic activities as noted above.

## Conclusion

The present study shows that TSPY is a male-specific genetic risk factor, whose ectopic expression could contribute partially to the male predominance of HCC. The ectopically expressed TSPY upregulates the expression of genes involved in cell-cycle progression, especially G<sub>2</sub>/M-phase, in HCC. In addition, TSPY may promote liver fibrosis and expedite an oncogenic transition to HCC via activation of the HA-HMMR signaling cascade, among others. Future studies on the mechanisms



of TSPY-mediated differential regulation of its downstream genes will provide novel insights on its oncogenic actions, prognostic values and potential therapeutic targets for effective clinical treatments of HCC.

## Additional files

**Additional file 1: Table S1.** Differentially expressed genes between TSPY-overexpressing and EGFP-control HuH-7 cells.

**Additional file 2: Figure S1.** Results of Ingenuity Pathway Analysis (IPA) using a stringent cutoff on expression level of DEGs.

**Additional file 3: Table S2.** Differentially expressed genes between the male TSPY-high HCCs and the male TSPY-silent HCCs.

**Additional file 4: Table S3.** DEGs commonly correlated with the TSPY expression level in both HuH-7 cells and clinical male HCC samples.

**Additional file 5: Figure S2.** Survival rates of the high-expresser patients (red lines) and the low-expresser patients (blue lines) for the 16TSPY downstream genes.

**Additional file 6: Figure S3.** Comparison of the gene expression levels of the 16 TSPY downstream genes among female non-tumor liver (NT),

female HCC, male non-tumor liver (NT), male TSPY-silent HCC (TS(-)), and male TSPY-high HCC (TS(++)) groups.

**Additional file 7: Table S4.** Detailed description of 16 genes potentially regulated by TSPY and associated with prognoses in HCC patients.

**Additional file 8: Figure S4.** Small molecule inhibitors for CDC25 and RRM2, the downstream pro-oncogenic molecules of TSPY, inhibited cell proliferation in hepatocellular carcinoma cell line HuH-7.

## Authors' contributions

TK and Y-FCL conceived the idea of TSPY as an oncogene in liver cancer. TK performed the experimental and data analyses; Y-FCL and TK co-wrote the manuscript. Both authors read and approved the final manuscript.

## Author details

<sup>1</sup> Division of Cell and Developmental Genetics, Department of Medicine, Veterans Affairs Medical Center, University of California, San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA. <sup>2</sup> Institute for Human Genetics, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143, USA.

## Acknowledgements

We thank Dr. Yunmin Li for technical assistance.

## Competing interests

The authors declare that they have no competing interests.

**Availability of data and materials**

Transcriptome data of HuH-7 cells will be submitted to the Gene Expression Omnibus database, and the accession numbers posted upon acceptance of the manuscript. All other reagents will be available upon request from the authors after the manuscript is published.

**Consent for publication**

All authors have read and consented for the publication of this manuscript.

**Ethics approval and consent to participate**

Not applicable.

**Funding**

This work is partially supported by a grant from the Department of Defense Peer-Reviewed Cancer Program to YFCL (CA150248) and a Merit-Review Grant IO1 BX004446 from the Department of Veterans Affairs. YFCL is a Research Career Scientist of the Department of Veterans Affairs.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 25 November 2018 Accepted: 27 February 2019

Published online: 04 March 2019

**References**

- Salo P, Kaariainen H, Petrovic V, Peltomaki P, Page DC, de la Chapelle A. Molecular mapping of the putative gonadoblastoma locus on the Y chromosome. *Genes Chromosomes Cancer*. 1995;14(3):210–4.
- Tsuchiya K, Reijo R, Page DC, Distchele CM. Gonadoblastoma: molecular definition of the susceptibility region on the Y chromosome. *Am J Hum Genet*. 1995;57(6):1400–7.
- Skaletsky H, Kuroda-Kawaguchi T, Minx PJ, Cordum HS, Hillier L, Brown LG, Repping S, Pyntikova T, Ali J, Bieri T, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. *Nature*. 2003;423(6942):825–37.
- Schnieders F, Dork T, Arneemann J, Vogel T, Werner M, Schmidtke J. Testis-specific protein, Y-encoded (TSPY) expression in testicular tissues. *Hum Mol Genet*. 1996;5(11):1801–7.
- Zhang JS, Yang-Feng TL, Muller U, Mohandas TK, de Jong PJ, Lau YF. Molecular isolation and characterization of an expressed gene from the human Y chromosome. *Hum Mol Genet*. 1992;1(9):717–26.
- Lau YF. Gonadoblastoma, testicular and prostate cancers, and the TSPY gene. *Am J Hum Genet*. 1999;64(4):921–7.
- Chae YC, Kim KB, Kang JY, Kim SR, Jung HS, Seo SB. Inhibition of FoxO1 acetylation by INHAT subunit SET/TAF- $\beta$  induces p21 transcription. *FEBS Lett*. 2014;588(17):2867–73.
- D'Arcy S, Martin KW, Panchenko T, Chen X, Bergeron S, Stargell LA, Black BE, Luger K. Chaperone Nap1 shields histone surfaces used in a nucleosome and can put H2A-H2B in an unconventional tetrameric form. *Mol Cell*. 2013;51(5):662–77.
- Loyola A, Almouzni G. Histone chaperones, a supporting role in the limelight. *Biochim Biophys Acta*. 2004;1677(1–3):3–11.
- Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. *Cell*. 2001;104(1):119–30.
- Kido T, Lau YF. The human Y-encoded testis-specific protein interacts functionally with eukaryotic translation elongation factor eEF1A, a putative oncoprotein. *Int J Cancer*. 2008;123(7):1573–85.
- Li Y, Lau YF. TSPY and its X-encoded homologue interact with cyclin B but exert contrasting functions on cyclin-dependent kinase 1 activities. *Oncogene*. 2008;27(47):6141–50.
- Li Y, Zhang DJ, Qiu Y, Kido T, Lau YC. The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants. *Hum Mol Genet*. 2017;26(5):901–12.
- Oram SW, Liu XX, Lee TL, Chan WY, Lau YF. TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. *BMC Cancer*. 2006;6:154.
- Kido T, Lau YF. The Y-located gonadoblastoma gene TSPY amplifies its own expression through a positive feedback loop in prostate cancer cells. *Biochem Biophys Res Commun*. 2014;446(1):206–11.
- Shen Y, Tu W, Liu Y, Yang X, Dong Q, Yang B, Xu J, Yan Y, Pei X, Liu M, et al. TSPY1 suppresses USP7-mediated p53 function and promotes spermatogonial proliferation. *Cell Death Dis*. 2018;9(5):542.
- Honecker F, Stoop H, de Krijger RR, Chris Lau YF, Bokemeyer C, Looijenga LH. Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. *J Pathol*. 2004;203(3):849–57.
- Kido T, Lau YF. A Cre gene directed by a human TSPY promoter is specific for germ cells and neurons. *Genesis*. 2005;42(4):263–75.
- Lau YF, Li Y, Kido T. Role of the Y-located putative gonadoblastoma gene in human spermatogenesis. *Syst Biol Reprod Med*. 2011;57(1–2):27–34.
- Honecker F, Stoop H, Mayer F, Bokemeyer C, Castrillon DH, Lau YF, Looijenga LH, Oosterhuis JW. Germ cell lineage differentiation in non-seminomatous germ cell tumours. *J Pathol*. 2006;208(3):395–400.
- Kersemaekers AM, Honecker F, Stoop H, Cools M, Molier M, Wolffenbuttel K, Bokemeyer C, Li Y, Lau YF, Oosterhuis JW, et al. Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY. *Hum Pathol*. 2005;36(5):512–21.
- Lau Y, Chou P, Iezzoni J, Alonzo J, Komuves L. Expression of a candidate gene for the gonadoblastoma locus in gonadoblastoma and testicular seminoma. *Cytogenet Cell Genet*. 2000;91(1–4):160–4.
- Li Y, Tabatabai ZL, Lee TL, Hatakeyama S, Ohyama C, Chan WY, Looijenga LH, Lau YF. The Y-encoded TSPY protein: a significant marker potentially plays a role in the pathogenesis of testicular germ cell tumors. *Hum Pathol*. 2007;38(10):1470–81.
- Li Y, Vilain E, Conte F, Rajpert-De Meyts E, Lau YF. Testis-specific protein Y-encoded gene is expressed in early and late stages of gonadoblastoma and testicular carcinoma in situ. *Urol Oncol*. 2007;25(2):141–6.
- Kido T, Schubert S, Schmidtke J, Lau YF. Expression of the human TSPY gene in the brains of transgenic mice suggests a potential role of this Y chromosome gene in neural functions. *J Genet Genom*. 2011;38:181–92.
- Kido T, Hatakeyama S, Ohyama C, Lau YF. Expression of the Y-encoded TSPY is associated with progression of prostate cancer. *Genes (Basel)*. 2010;1(2):283–93.
- Kido T, Lau YC. Identification of a TSPY co-expression network associated with DNA hypomethylation and tumor gene expression in somatic cancers. *J Genet Genom*. 2016;43(10):577–85.
- Kido T, Lo RC, Li Y, Lee J, Tabatabai ZL, Ng IO, Lau YF. The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma. *Hum Pathol*. 2014;45(9):1847–58.
- Lau YF, Lau HW, Komuves LG. Expression pattern of a gonadoblastoma candidate gene suggests a role of the Y chromosome in prostate cancer. *Cytogenet Genome Res*. 2003;101(3–4):250–60.
- Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, Pang XW, Zhang Y, Chen WF. TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. *Br J Cancer*. 2005;93(4):458–63.
- World Health Organization. <https://www.who.int/cancer/resources/keyfacts/en/>. Accessed 23 Nov 2018.
- Global Burden of Disease Cancer C, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, Allen C, Alsharif U, Alvis-Guzman N, Amini E, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. *JAMA Oncol*. 2018;4(11):1553–68.
- Liu P, Xie SH, Hu S, Cheng X, Gao T, Zhang C, Song Z. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. *Oncotarget*. 2017;8(40):68131–7.
- Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, Leung C, Wang HH, Wong GL, Wong VW, et al. International incidence and mortality trends of liver cancer: a global profile. *Sci Rep*. 2017;7:45846.
- Cheung OK, Cheng AS. Gender differences in adipocyte metabolism and liver cancer progression. *Front Genet*. 2016;7:168.



36. Hartwell HJ, Petrosky KY, Fox JG, Horseman ND, Rogers AB. Prolactin prevents hepatocellular carcinoma by restricting innate immune activation of c-Myc in mice. *Proc Natl Acad Sci USA*. 2014;111(31):11455–60.
37. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science*. 2007;317(5834):121–4.
38. Clocchiatti A, Cora E, Zhang Y, Dotto GP. Sexual dimorphism in cancer. *Nat Rev Cancer*. 2016;16(5):330–9.
39. Ma WL, Lai HC, Yeh S, Cai X, Chang C. Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis. *Endocr Relat Cancer*. 2014;21(3):R165–82.
40. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. *Oncology*. 2010;78(Suppl 1):172–9.
41. Tomczak K, Czerwinska P, Wznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. *Contemp Oncol (Pozn)*. 2015;19(1A):A68–77.
42. Hockemeyer D, Soldner F, Cook EG, Gao Q, Mitalipova M, Jaenisch R. A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. *Cell Stem Cell*. 2008;3(3):346–53.
43. Kido T, Sun Z, Lau YC. Aberrant activation of the human sex-determining gene in early embryonic development results in postnatal growth retardation and lethality in mice. *Sci Rep*. 2017;7(1):4113.
44. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics*. 2009;25(9):1105–11.
45. FastQC: a quality control tool for high throughput sequence data. <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>. Accessed 28 Mar 2017.
46. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. *Bioinformatics*. 2014;30(7):923–30.
47. Sun J, Nishiyama T, Shimizu K, Kadota K. TCC: an R package for comparing tag count data with robust normalization strategies. *BMC Bioinform*. 2013;14:219.
48. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, et al. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. *Nucleic Acids Res*. 2007;35(Web Server issue):W169–75.
49. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res*. 2017;45(D1):D353–61.
50. Goldman M, Craft B, Kamath A, Brooks AN, Zhu J, Haussler D. The UCSC Xena platform for cancer genomics data visualization and interpretation. *bioRxiv*. 2018. <https://doi.org/10.1101/326470>.
51. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinform*. 2011;12:323.
52. Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, Benfiteas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. *Science*. 2017;357(6352):eaan2507.
53. Kramer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in ingenuity pathway analysis. *Bioinformatics*. 2014;30(4):523–30.
54. Li Y, Zheng M, Lau YF. The sex-determining factors SRY and SOX9 regulate similar target genes and promote testis cord formation during testicular differentiation. *Cell Rep*. 2014;8(3):723–33.
55. Liu R, Zhang H, Zhang Y, Li S, Wang X, Wang X, Wang C, Liu B, Zen K, Zhang CY, et al. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha acts as a tumor suppressor in hepatocellular carcinoma. *Tumour Biol*. 2017;39(4):1010428317695031.
56. Wang X, Liao Z, Bai Z, He Y, Duan J, Wei L. MiR-93-5p Promotes cell proliferation through down-regulating PPARGC1A in hepatocellular carcinoma cells by bioinformatics analysis and experimental verification. *Genes (Basel)*. 2018;9(1):51.
57. Qiu X, Zheng J, Guo X, Gao X, Liu H, Tu Y, Zhang Y. Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. *Mol Cell Biochem*. 2013;378(1–2):99–106.
58. Cui M, Sun J, Hou J, Fang T, Wang X, Ge C, Zhao F, Chen T, Xie H, Cui Y, et al. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma. *Tumour Biol*. 2016;37(10):13521–31.
59. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent post-transcriptional silencing of SOCS2. *Hepatology*. 2018;67(6):2254–70.
60. Mashima H, Ueda N, Ohno H, Suzuki J, Ohnishi H, Yasuda H, Tsuchida T, Kanamaru C, Makita N, Iiri T, et al. A novel mitochondrial Ca2+-dependent solute carrier in the liver identified by mRNA differential display. *J Biol Chem*. 2003;278(11):9520–7.
61. Pathak T, Trebak M. Mitochondrial Ca(2+) signaling. *Pharmacol Ther*. 2018;192:112–23.
62. Lau YF, Li Y, Kido T. Gonadoblastoma locus and the TSPY gene on the human Y chromosome. *Birth Defects Res C Embryo Today*. 2009;87(1):114–22.
63. Casimir GJ, Mulier S, Hanssens L, Zylberberg K, Duchateau J. Gender differences in inflammatory markers in children. *Shock*. 2010;33(3):258–62.
64. Gillies GE, Pienaar IS, Vohra S, Qamhawi Z. Sex differences in Parkinson's disease. *Front Neuroendocrinol*. 2014;35(3):370–84.
65. Maan AA, Eales J, Akbarov A, Rowland J, Xu X, Jobling MA, Charchar FJ, Tomaszewski M. The Y chromosome: a blueprint for men's health? *Eur J Hum Genet*. 2017;25(11):1181–8.
66. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. *Circulation*. 2011;124(19):2145–54.
67. Rathod KS, Kapil V, Velmurugan S, Khambata RS, Siddique U, Khan S, Van Eijl S, Gee LC, Bansal J, Pitrola K, et al. Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans. *J Clin Invest*. 2017;127(1):169–82.
68. Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. *Physiol Rev*. 2017;97(1):1–37.
69. Pike CJ. Sex and the development of Alzheimer's disease. *J Neurosci Res*. 2017;95(1–2):671–80.
70. Kalra M, Mayes J, Assefa S, Kaul AK, Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. *World J Gastroenterol*. 2008;14(39):5945–61.
71. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. *Cell*. 2012;148(1–2):72–83.
72. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. *Trends Mol Med*. 2008;14(3):109–19.
73. Chiu CM, Yeh SH, Chen PJ, Kuo TJ, Chang CJ, Chen PJ, Yang WJ, Chen DS. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. *Proc Natl Acad Sci USA*. 2007;104(8):2571–8.
74. Wang SH, Yeh SH, Chen PJ. The driving circuit of HBx and androgen receptor in HBV-related hepatocarcinogenesis. *Gut*. 2014;63(11):1688–9.
75. Wu MH, Ma WL, Hsu CL, Chen YL, Ou JH, Ryan CK, Hung YC, Yeh S, Chang C. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. *Sci Transl Med*. 2010;2(32):32ra5.
76. Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang SH, Tsai TF, Chen DS, Chen PJ. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. *Hepatology*. 2009;49(5):1515–24.
77. Zhu R, Zhang JS, Zhu YZ, Fan J, Mao Y, Chen Q, Zhu HG. HBx-induced androgen receptor expression in HBV-associated hepatocarcinoma is independent of the methylation status of its promoter. *Histol Histopathol*. 2011;26(1):23–35.
78. Tian YE, Xie XU, Lin Y, Tan G, Zhong WU. Androgen receptor in hepatocarcinogenesis: recent developments and perspectives. *Oncol Lett*. 2015;9(5):1983–8.
79. Falleti E, Fabris C, Toniutto P, Fontanini E, Cussigh A, Bitetto D, Fumolo E, Fornasiere E, Bragagnini W, Pinato DJ, et al. Interleukin-6 polymorphisms and gender: relationship with the occurrence of hepatocellular carcinoma in patients with end-stage liver disease. *Oncology*. 2009;77(5):304–13.
80. Hamaoka K, Nagoshi S, Sugawara K, Naiki K, Uchida Y, Inao M, Nakayama N, Fujiwara K, Mochida S. SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV. *Hepatol Int*. 2013;7(2):683–92.
81. Kido T, Ou JH, Lau YF. The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway. *PLoS ONE*. 2011;6(7):e22979.



82. Bayin NS, Frenster JD, Kane JR, Rubenstein J, Modrek AS, Baitalmal R, Dolgalev I, Rudzenski K, Scarabottolo L, Crespi D, et al. GPR133 (ADGRD1), an adhesion G-protein-coupled receptor, is necessary for glioblastoma growth. *Oncogenesis*. 2016;5(10):e263.
83. He X, Liao W, Li Y, Wang Y, Chen Q, Jin J, He S. Upregulation of hyaluronan-mediated motility receptor in hepatocellular carcinoma predicts poor survival. *Oncol Lett*. 2015;10(6):3639–46.
84. Lee WH, Chen LC, Lee CJ, Huang CC, Ho YS, Yang PS, Ho CT, Chang HL, Lin IH, Chang HW, et al. DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint. *Int J Cancer*. 2019;144(3):615–30.
85. Shao J, Xu Z, Peng X, Chen M, Zhu Y, Xu L, Zhu H, Yang B, Luo P, He Q. Gefitinib synergizes with irinotecan to suppress hepatocellular carcinoma via antagonizing Rad51-Mediated DNA-repair. *PLoS ONE*. 2016;11(1):e0146968.
86. Tilghman J, Wu H, Sang Y, Shi X, Guerrero-Cazares H, Quinones-Hinojosa A, Eberhart CG, Laterra J, Ying M. HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells. *Cancer Res*. 2014;74(11):3168–79.
87. Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. *J Pharmacol Exp Ther*. 2010;335(3):830–40.
88. Yan X, Chua MS, He J, So SK. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. *Mol Cancer*. 2008;7:19.
89. Zhong Y, Yang J, Xu WW, Wang Y, Zheng CC, Li B, He QY. KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition. *Oncogene*. 2017;36(44):6177–89.
90. Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK. High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma. *Gut Liver*. 2014;8(6):662–8.
91. Zhu P, Jin J, Liao Y, Li J, Yu XZ, Liao W, He S. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma. *Oncotarget*. 2015;6(38):41383–97.
92. Niedworok C, Kretschmer I, Rock K, Vom Dorp F, Szarvas T, Hess J, Freudenberger T, Melchior-Becker A, Rubben H, Fischer JW. The impact of the receptor of hyaluronan-mediated motility (RHAMM) on human urothelial transitional cell cancer of the bladder. *PLoS ONE*. 2013;8(9):e75681.
93. Rizzardi AE, Vogel RI, Koopmeiners JS, Forster CL, Marston LO, Rosener NK, Akentieva N, Price MA, Metzger GJ, Warlick CA, et al. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. *Cancer*. 2014;120(12):1800–9.
94. Mele V, Sokol L, Kolzer VH, Pfaff D, Muraro MG, Keller I, Stefan Z, Centeno I, Terracciano LM, Dawson H, et al. The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer. *Oncotarget*. 2017;8(41):70617–29.
95. Jordan AR, Racine RR, Hennig MJ, Lokeshwar VB. The role of CD44 in disease pathophysiology and targeted treatment. *Front Immunol*. 2015;6:182.
96. Gudowska M, Gruszewska E, Panasiuk A, Cylwik B, Flisiak R, Swiderska M, Szmitkowski M, Chrostek L. Hyaluronic acid concentration in liver diseases. *Clin Exp Med*. 2016;16(4):523–8.
97. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? *J Cell Sci*. 2008;121(Pt 7):925–32.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

